Marc Chimowitz to Treatment Outcome
This is a "connection" page, showing publications Marc Chimowitz has written about Treatment Outcome.
Connection Strength
0.675
-
Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial. J Stroke Cerebrovasc Dis. 2020 Dec; 29(12):105254.
Score: 0.077
-
Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017 Jan 24; 88(4):379-385.
Score: 0.059
-
Enrollment volume effect on risk factor control and outcomes in the SAMMPRIS trial. Neurology. 2015 Dec 15; 85(24):2090-7.
Score: 0.055
-
The challenge of stroke prevention with intracranial arterial stenosis. Curr Cardiol Rep. 2013 Dec; 15(12):422.
Score: 0.048
-
Intracranial stenting: SAMMPRIS. Stroke. 2013 Jun; 44(6 Suppl 1):S41-4.
Score: 0.046
-
Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. J Stroke Cerebrovasc Dis. 2011 Jul-Aug; 20(4):357-68.
Score: 0.040
-
Re: Turk et al and the "how do we spin wingspan?" commentary. AJNR Am J Neuroradiol. 2008 Sep; 29(8):e69; author reply e70.
Score: 0.032
-
Mitigating the effects of COVID-19 pandemic on controlling vascular risk factors among participants in a carotid stenosis trial. J Stroke Cerebrovasc Dis. 2020 Dec; 29(12):105362.
Score: 0.019
-
Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial. Stroke. 2020 10; 51(10):2960-2971.
Score: 0.019
-
Best treatment for intracranial arterial stenosis? 50 years of uncertainty. The WASID Investigators. Neurology. 2000 Aug 22; 55(4):465-6.
Score: 0.019
-
Impact of Baseline Features and Risk Factor Control on Cognitive Function in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. Cerebrovasc Dis. 2019; 47(1-2):24-31.
Score: 0.017
-
Type and Duration of Exercise in the SAMMPRIS Trial. Neurologist. 2019 Jan; 24(1):10-12.
Score: 0.017
-
Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale. J Biopharm Stat. 2019; 29(1):82-97.
Score: 0.016
-
Relationship between Risk Factor Control and Compliance with a Lifestyle Modification Program in the Stenting Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis Trial. J Stroke Cerebrovasc Dis. 2018 Mar; 27(3):801-805.
Score: 0.016
-
Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials. Int J Stroke. 2017 10; 12(7):770-778.
Score: 0.015
-
Is There Benefit from Stenting on Cognitive Function in Intracranial Atherosclerosis? Cerebrovasc Dis. 2017; 43(1-2):31-35.
Score: 0.015
-
Impact of the New American Heart Association/American Stroke Association Definition of Stroke on the Results of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. J Stroke Cerebrovasc Dis. 2017 Jan; 26(1):108-115.
Score: 0.015
-
Frequency, Risk Factors, and Outcome of Coexistent Small Vessel Disease and Intracranial Arterial Stenosis: Results From the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. JAMA Neurol. 2016 Jan; 73(1):36-42.
Score: 0.014
-
Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis? Stroke. 2015 Nov; 46(11):3282-4.
Score: 0.014
-
Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis. Stroke. 2015 Mar; 46(3):775-9.
Score: 0.013
-
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014 Jan 25; 383(9914):333-41.
Score: 0.012
-
Mechanisms of stroke after intracranial angioplasty and stenting in the SAMMPRIS trial. Neurosurgery. 2013 May; 72(5):777-95; discussion 795.
Score: 0.011
-
Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke. 2012 Oct; 43(10):2682-8.
Score: 0.011
-
Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. J Neurointerv Surg. 2013 Nov; 5(6):528-33.
Score: 0.011
-
Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):e51-60.
Score: 0.011
-
Utilization of CT perfusion patient selection for mechanical thrombectomy irrespective of time: a comparison of functional outcomes and complications. J Neurointerv Surg. 2013 Nov; 5(6):518-22.
Score: 0.011
-
CT perfusion-guided patient selection for endovascular treatment of acute ischemic stroke is safe and effective. J Neurointerv Surg. 2012 Jul; 4(4):261-5.
Score: 0.010
-
Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. Stroke. 2009 Feb; 40(2):505-9.
Score: 0.008
-
The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology. 2008 Apr 22; 70(17):1518-24.
Score: 0.008
-
Gender differences in outcomes among patients with symptomatic intracranial arterial stenosis. Stroke. 2007 Jul; 38(7):2055-62.
Score: 0.008
-
Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology. 2006 Oct 10; 67(7):1275-8.
Score: 0.007